CAR T-Cell Therapy Market is Projected to Grow at the CAGR of 44.79% during the Forecast Period from 2020-2030.
According to BIS Research, CAR T-cell are genetically engineered to produce special structures called chimeric antigen receptors (CARs) for use in CAR T-cell therapy or immunotherapy. These especially altered T-cells specifically target cancer cells. CAR T-cell therapies are used predominantly in the treatment of different hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The scope of the of global CAR T-cell therapy market includes T-cell immunotherapies (focusing particularly on CAR T-cell therapies) that are used for the treatment of different hematologic malignancies and other cancer-related disorders. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric populatio...